Geron (GERN) Shares Outstanding (Diluted Average) (2020 - 2026)
Geron's (GERN) quarterly Shares Outstanding (Diluted Average) came in at $669375.0 in Q1 2026, up 0.52% year-on-year from $665905.0 in Q1 2025, and down 99.9% quarter-over-quarter from $666.7 million in Q4 2025.
Geron (GERN) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Geron has disclosed Shares Outstanding (Diluted Average) across 7 years of filings, most recently posting $669375.0 for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $669375.0, up 0.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $669375.0 (up 0.52% YoY), and the FY2025 annual result was $666.7 million, up 3.19% from the prior year.
- Shares Outstanding (Diluted Average) came in at $669375.0 for Q1 2026 at Geron, down from $666.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $667.1 million in Q3 2025 to a low of $665905.0 in Q1 2025.
- The 5-year median for Shares Outstanding (Diluted Average) is $570.6 million (2023), against an average of $485.5 million.
- Across the five-year window, Shares Outstanding (Diluted Average) surged 63.96% in 2023 and tumbled 99.89% in 2025, its largest moves.
- Geron's Shares Outstanding (Diluted Average) stood at $380.8 million in 2022, then soared by 49.86% to $570.6 million in 2023, then rose by 13.21% to $646.0 million in 2024, then climbed by 3.19% to $666.7 million in 2025, then slumped by 99.9% to $669375.0 in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $669375.0 (Q1 2026), $666.7 million (Q4 2025), and $667.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 92.44 Mn |
| 10 | Geron | 753,046.88 | 753,046.88 | - | 669,375.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 669,375.00 |
| Dec 31, 2025 | 666.66 Mn |
| Sep 30, 2025 | 667.10 Mn |
| Jun 30, 2025 | 666.04 Mn |
| Mar 31, 2025 | 665,905.00 |
| Dec 31, 2024 | 646.03 Mn |
| Sep 30, 2024 | 639.93 Mn |
| Jun 30, 2024 | 628.70 Mn |
| Mar 31, 2024 | 603.49 Mn |
| Dec 31, 2023 | 570.65 Mn |
| Sep 30, 2023 | 579.51 Mn |
| Jun 30, 2023 | 553.77 Mn |
| Mar 31, 2023 | 544.46 Mn |
| Dec 31, 2022 | 380.78 Mn |
| Sep 30, 2022 | 405.24 Mn |
| Jun 30, 2022 | 368.17 Mn |
| Mar 31, 2022 | 332.07 Mn |
| Dec 31, 2021 | 327.63 Mn |
| Sep 30, 2021 | 326.55 Mn |
| Jun 30, 2021 | 327.03 Mn |